316 related articles for article (PubMed ID: 38398257)
1. Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review.
Ferri N; Ruscica M; Fazio S; Corsini A
J Clin Med; 2024 Feb; 13(4):. PubMed ID: 38398257
[TBL] [Abstract][Full Text] [Related]
2. New Strategies for Lowering Low Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention.
Gaine SP; Quispe R; Patel J; Michos ED
Curr Cardiovasc Risk Rep; 2022 Sep; 16(9):69-78. PubMed ID: 36213094
[TBL] [Abstract][Full Text] [Related]
3. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.
Michaeli DT; Michaeli JC; Albers S; Boch T; Michaeli T
Am J Cardiovasc Drugs; 2023 Sep; 23(5):477-495. PubMed ID: 37486464
[TBL] [Abstract][Full Text] [Related]
4. Bempedoic Acid's Use as an Adjunct in Lowering Low-Density Lipoprotein Cholesterol in Patients With Coronary Artery Disease: A Systematic Review.
Goit R; Saddik SE; Dawood SN; Rabih AM; Niaj A; Raman A; Uprety M; Calero MJ; Villanueva MRB; Joshaghani N; Villa N; Badla O; Khan S
Cureus; 2022 Oct; 14(10):e29891. PubMed ID: 36348882
[TBL] [Abstract][Full Text] [Related]
5. Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol.
Bardolia C; Amin NS; Turgeon J
Front Cardiovasc Med; 2021; 8():789931. PubMed ID: 34869702
[TBL] [Abstract][Full Text] [Related]
6. Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias.
Rached F; Santos RD
Curr Cardiol Rep; 2021 Jun; 23(7):83. PubMed ID: 34081216
[TBL] [Abstract][Full Text] [Related]
7. Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease.
Albosta MS; Grant JK; Taub P; Blumenthal RS; Martin SS; Michos ED
Vasc Health Risk Manag; 2023; 19():421-431. PubMed ID: 37434791
[TBL] [Abstract][Full Text] [Related]
8. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins.
Warden BA; Duell PB
J Cardiovasc Pharmacol; 2021 Aug; 78(2):e157-e174. PubMed ID: 33990512
[TBL] [Abstract][Full Text] [Related]
9. Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus Seminar.
Preiss D; Tobert JA; Hovingh GK; Reith C
J Am Coll Cardiol; 2020 Apr; 75(16):1945-1955. PubMed ID: 32327106
[TBL] [Abstract][Full Text] [Related]
10. PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients.
Gunta SP; O'Keefe JH; O'Keefe EL; Lavie CJ
Prog Cardiovasc Dis; 2023; 79():12-18. PubMed ID: 36871887
[TBL] [Abstract][Full Text] [Related]
11. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
[TBL] [Abstract][Full Text] [Related]
12. Clinical Pharmacology of Statins: an Update.
Ferri N; Corsini A
Curr Atheroscler Rep; 2020 Jun; 22(7):26. PubMed ID: 32494971
[TBL] [Abstract][Full Text] [Related]
13. Bempedoic acid for the treatment of dyslipidemia.
Marrs JC; Anderson SL
Drugs Context; 2020; 9():. PubMed ID: 32922503
[TBL] [Abstract][Full Text] [Related]
14. Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential.
Brandts J; Ray KK
Expert Opin Investig Drugs; 2020 Aug; 29(8):763-770. PubMed ID: 32564642
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy.
Tomlinson B; Chan P; Zhang Y; Lam CWK
Expert Opin Pharmacother; 2020 Dec; 21(17):2137-2151. PubMed ID: 32772741
[TBL] [Abstract][Full Text] [Related]
16. Emerging lipid lowering agents targeting LDL cholesterol.
Wójcik C
Postgrad Med; 2020 Jun; 132(5):433-440. PubMed ID: 32243228
[TBL] [Abstract][Full Text] [Related]
17. The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function.
Di Costanzo A; Indolfi C; Sorrentino S; Esposito G; Spaccarotella CAM
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511498
[TBL] [Abstract][Full Text] [Related]
18. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.
Rubino J; MacDougall DE; Sterling LR; Kelly SE; McKenney JM; Lalwani ND
J Clin Lipidol; 2021; 15(4):593-601. PubMed ID: 34172394
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
